Welcome to the CLL Clinical Roadmap chaired by Dr. Susan O'Brien and Dr. John Gribben. The CLL Roadmap is a free to access educational curriculum featuring presentations from world leading experts in their field. Every month we will have guest speakers presenting findings on a hot topic and the chairs will join to participate in a debate and question and answers session to dive deep into the subject.
Please register below to get free access to the content and to receive the monthly webinar direct to your email.
University of California Irvine Medical Center, USA
Barts Cancer Institute, London, UK
University of Cologne, Germany
Othman Al-Sawaf is a haematologist and medical oncologist at the University Hospital Cologne, Cologne, Germany, and study physician at the German CLL Study Group (GCLLSG).
He studied medicine at the Medical School of RWTH Aachen University in Aachen, Germany, and joined the Department I of Internal Medicine I of Professor Michael Hallek at the University Hospital of Cologne in 2016. In 2020 he also joined the laboratory of Professor Charles Swanton at the Francis Crick Institute in London as a visiting scientist.
He works as coordinating physician and principal investigator for national and international phase I to III trials. In addition to his clinical trial work, he is interested in the principles of cancer evolution & metabolism. His research focusses on computational approaches for the discovery and development of new treatment strategies in clinical oncology.
Venetoclax pivotal trials, latest data:
CLL 14 Update
Peter MacCallum Cancer Centre, Melbourne, Australia
Professor John Seymour AM is a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre, and the Director of the integrated Haematology Department of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia.
He received his MB, BS degrees from the University of Melbourne in 1987, completed a translational research fellowship at the MD Anderson Cancer Center in Houston, and subsequently received their Distinguished Alumnus award in 2011. He also completed PhD studies in the pathobiology of haematopoietic growth factors at the Ludwig Institute for Cancer Research. Professor Seymour is a member of several national and international scientific committees including, Cancer Australia Advisory Groups, the Scientific Advisory Committee for the International Conference on Malignant Lymphoma, Medical Advisory Board of the Lymphoma Coalition, and the Board of Directors of the International Extranodal Lymphoma Study Group.
He served for more than a decade as Executive member and Chairman of the major national clinical trials co-operative group in haematologic malignancies, the Australasian Leukaemia & Lymphoma Group. He is a frequent invited speaker nationally and internationally, is a member of numerous professional societies, an Editor-in-Chief of Leukemia & Lymphoma, and currently on the editorial boards of Blood and the British Journal of Haematology.
He has authored 18 book chapters, >500 peer reviewed publications (with >25,000 literature citations), and >700 conference abstracts. Actively involved in a broad range of collaborative research, Professor Seymour has been has been the principal investigator on >85 clinical trials and chief investigator on competitive grants awarded >AUD$18 million funding in the last 10 years. In 2015 he was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.
Venetociax pivotal trials, latest data: Murano Update
Feinstein Institutes for Medical Research, New York, USA
Jacqueline Barrientos, MD, is Attending Physician at the Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program of the Division of Hematology and Medical Oncology, Northwell Cancer Institute in New York, USA, and Associate Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell. Dr Barrientos received her medical degree from the Ponce School of Medicine in Puerto Rico, USA. She was elected vice-president of the Alpha Omega Alpha Honor Medical Society and received two research awards from the Howard Hughes Medical Institute. She completed her residency in internal medicine at Yale-New Haven Hospital, Yale School of Medicine, and her fellowship in hematology and medical oncology at New York Presbyterian Hospital of Weill Cornell Medical College, where she was Chief Fellow. Dr Barrientos participates in multi-institutional clinical trials with the CLL Research Consortium (CRC) and the Alliance for Clinical Trials in Oncology. She is a member of the American Society of Clinical Oncology and the American Society of Hematology. She is the recipient of the 2015 ASH-AMFDP (American Society of Hematology – Harold Amos Medical Faculty Development Program) career development award to study CLL and lymphoma.
Long term follow-up on approved BTKi
in CLL: Ibrutiniba
Università Vita-Salute San Raffaele, Milan, Italy
Paolo Ghia, MD, PhD, is a Professor at the Università Vita-Salute San Raffaele, Milan, Italy, and director of the Strategic Research Program on CLL.
Dr Ghia received his medical degree from the University of Torino, Torino, Italy, and subsequently completed a residency in internal medicine. He then received a PhD at the Basel Institute for Immunology, Basel, Switzerland. Afterwards, Dr Ghia continued his studies at the Dana-Farber Cancer Institute at Harvard Medical School, Boston, MA.
Recent advances in lymphoma clinical trials
Hospital de Sant Pau i Santa Creu, Barcelona, Spain
Carol Moreno, MD, PhD, is a Senior Consultant in the Department of Hematology at the Hospital de Sant Pau i Santa Creu, Autonomous University of Barcelona, Barcelona, Spain. She combines clinical work with research activity at the Biomedical Research Institute of Sant Pau. Dr Moreno received her MBBS and her MD degrees from the University of Barcelona. She then conducted post-doctoral research at the Feinstein Institutes for Medical Research, New York, NY.
Dr Moreno currently serves as a board member of the European Research Initiative on CLL (ERIC) and for the Spanish Group on Hematological Malignancies in the Elderly. Furthermore, Dr Moreno is a member of the Scientific Committee of the José Carreras Research Institute and the European Hematology Association (EHA).
PKI3 inhibitors in CLL: Idelalisib + Rituximab
Tennessee Oncology, Nashville, USA
Ian Flinn, MD, PhD, attended the Johns Hopkins University School of Medicine, Baltimore, MD, before completing residency training at the University of Michigan Medical Center, Ann Arbor, MI, and a Hematology and Medical Oncology fellowship at Johns Hopkins. He currently practices as a Hematologist/Oncologist at the Tennessee Oncology Center for Blood Cancers, Nashville, TN, and is Director of Lymphoma Research at the Sarah Cannon Research Institute, Nashville, TN. Dr Flinn is a member of the CLL Research Consortium, the American Society of Clinical Oncology and the American Society of Hematology.
PKI3 inhibitors in CLL: Duvelisib
Dana-Farber Cancer Institute, Boston, USA
Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction in MB&B. She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize for research accomplishment in the graduating class. She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at the Dana-Farber Cancer Institute. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL.
Her particular interests include the development of novel targeted therapeutics for CLL, as well as the genomics of CLL. She has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL. In the area of genomics she has been instrumental in the description of the somatic mutation profile of CLL, and is now particularly interested in the implementation of genomic technology in the clinic, including for prognosis and targeted therapy. She also has a longstanding research interest and focus on the inherited predisposition to CLL. To date she has published over 150 papers in the scientific literature, predominantly in CLL. She is an active member of the CLL Research Consortium and serves on the Alliance Leukemia and Leukemia Correlative Science Committees as well as the NIH Cancer Biomarkers Study Section. In 2014 she was the recipient of two awards from Dana-Farber Cancer Institute, the Clinical Innovation Award, as well as the George Canellos Award for Excellence in Clinical Investigation and Patient Care. She enjoys a worldwide reputation as a CLL expert and is in much demand as an international speaker.
Agents close to approval in CLL: Zanubrutinib
Barts Cancer Institute, London, UK
Agents close to approval in CLL: Umbralisib
University of Cologne, Germany
Othman Al-Sawaf is a haematologist and medical oncologist at the University Hospital Cologne, Cologne, Germany, and study physician at the German CLL Study Group (GCLLSG).
He studied medicine at the Medical School of RWTH Aachen University in Aachen, Germany, and joined the Department I of Internal Medicine I of Professor Michael Hallek at the University Hospital of Cologne in 2016. In 2020 he also joined the laboratory of Professor Charles Swanton at the Francis Crick Institute in London as a visiting scientist.
He works as coordinating physician and principal investigator for national and international phase I to III trials. In addition to his clinical trial work, he is interested in the principles of cancer evolution & metabolism. His research focusses on computational approaches for the discovery and development of new treatment strategies in clinical oncology.
Venetoclax pivotal trials, latest data:
CLL 14 Update
Peter MacCallum Cancer Centre, Melbourne, Australia
Professor John Seymour AM is a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre, and the Director of the integrated Haematology Department of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia.
He received his MB, BS degrees from the University of Melbourne in 1987, completed a translational research fellowship at the MD Anderson Cancer Center in Houston, and subsequently received their Distinguished Alumnus award in 2011. He also completed PhD studies in the pathobiology of haematopoietic growth factors at the Ludwig Institute for Cancer Research. Professor Seymour is a member of several national and international scientific committees including, Cancer Australia Advisory Groups, the Scientific Advisory Committee for the International Conference on Malignant Lymphoma, Medical Advisory Board of the Lymphoma Coalition, and the Board of Directors of the International Extranodal Lymphoma Study Group.
He served for more than a decade as Executive member and Chairman of the major national clinical trials co-operative group in haematologic malignancies, the Australasian Leukaemia & Lymphoma Group. He is a frequent invited speaker nationally and internationally, is a member of numerous professional societies, an Editor-in-Chief of Leukemia & Lymphoma, and currently on the editorial boards of Blood and the British Journal of Haematology.
He has authored 18 book chapters, >500 peer reviewed publications (with >25,000 literature citations), and >700 conference abstracts. Actively involved in a broad range of collaborative research, Professor Seymour has been has been the principal investigator on >85 clinical trials and chief investigator on competitive grants awarded >AUD$18 million funding in the last 10 years. In 2015 he was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.
Venetociax pivotal trials, latest data: Murano Update
Feinstein Institutes for Medical Research, New York, USA
Jacqueline Barrientos, MD, is Attending Physician at the Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program of the Division of Hematology and Medical Oncology, Northwell Cancer Institute in New York, USA, and Associate Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell. Dr Barrientos received her medical degree from the Ponce School of Medicine in Puerto Rico, USA. She was elected vice-president of the Alpha Omega Alpha Honor Medical Society and received two research awards from the Howard Hughes Medical Institute. She completed her residency in internal medicine at Yale-New Haven Hospital, Yale School of Medicine, and her fellowship in hematology and medical oncology at New York Presbyterian Hospital of Weill Cornell Medical College, where she was Chief Fellow. Dr Barrientos participates in multi-institutional clinical trials with the CLL Research Consortium (CRC) and the Alliance for Clinical Trials in Oncology. She is a member of the American Society of Clinical Oncology and the American Society of Hematology. She is the recipient of the 2015 ASH-AMFDP (American Society of Hematology – Harold Amos Medical Faculty Development Program) career development award to study CLL and lymphoma.
Long term follow-up on approved BTKi
in CLL: Ibrutiniba
Università Vita-Salute San Raffaele, Milan, Italy
Paolo Ghia, MD, PhD, is a Professor at the Università Vita-Salute San Raffaele, Milan, Italy, and director of the Strategic Research Program on CLL.
Dr Ghia received his medical degree from the University of Torino, Torino, Italy, and subsequently completed a residency in internal medicine. He then received a PhD at the Basel Institute for Immunology, Basel, Switzerland. Afterwards, Dr Ghia continued his studies at the Dana-Farber Cancer Institute at Harvard Medical School, Boston, MA.
Recent advances in lymphoma clinical trials
Hospital de Sant Pau i Santa Creu, Barcelona, Spain
Carol Moreno, MD, PhD, is a Senior Consultant in the Department of Hematology at the Hospital de Sant Pau i Santa Creu, Autonomous University of Barcelona, Barcelona, Spain. She combines clinical work with research activity at the Biomedical Research Institute of Sant Pau. Dr Moreno received her MBBS and her MD degrees from the University of Barcelona. She then conducted post-doctoral research at the Feinstein Institutes for Medical Research, New York, NY.
Dr Moreno currently serves as a board member of the European Research Initiative on CLL (ERIC) and for the Spanish Group on Hematological Malignancies in the Elderly. Furthermore, Dr Moreno is a member of the Scientific Committee of the José Carreras Research Institute and the European Hematology Association (EHA).
PKI3 inhibitors in CLL: Idelalisib + Rituximab
Tennessee Oncology, Nashville, USA
Ian Flinn, MD, PhD, attended the Johns Hopkins University School of Medicine, Baltimore, MD, before completing residency training at the University of Michigan Medical Center, Ann Arbor, MI, and a Hematology and Medical Oncology fellowship at Johns Hopkins. He currently practices as a Hematologist/Oncologist at the Tennessee Oncology Center for Blood Cancers, Nashville, TN, and is Director of Lymphoma Research at the Sarah Cannon Research Institute, Nashville, TN. Dr Flinn is a member of the CLL Research Consortium, the American Society of Clinical Oncology and the American Society of Hematology.
PKI3 inhibitors in CLL: Duvelisib
Dana-Farber Cancer Institute, Boston, USA
Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Dr. Brown completed a B.S. and M.S. simultaneously in molecular biophysics and biochemistry (MB&B) at Yale, graduating summa cum laude with distinction in MB&B. She proceeded to Harvard Medical School where she received her MD and PhD in molecular genetics in 1998 and was awarded the James Tolbert Shipley Prize for research accomplishment in the graduating class. She then served as an intern and resident in Internal Medicine at Massachusetts General Hospital followed by fellowship in Hematology and Medical Oncology at the Dana-Farber Cancer Institute. Dr. Brown joined the faculty of DFCI and Harvard Medical School in 2004, where she has an active clinical-translational research program in CLL.
Her particular interests include the development of novel targeted therapeutics for CLL, as well as the genomics of CLL. She has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL. In the area of genomics she has been instrumental in the description of the somatic mutation profile of CLL, and is now particularly interested in the implementation of genomic technology in the clinic, including for prognosis and targeted therapy. She also has a longstanding research interest and focus on the inherited predisposition to CLL. To date she has published over 150 papers in the scientific literature, predominantly in CLL. She is an active member of the CLL Research Consortium and serves on the Alliance Leukemia and Leukemia Correlative Science Committees as well as the NIH Cancer Biomarkers Study Section. In 2014 she was the recipient of two awards from Dana-Farber Cancer Institute, the Clinical Innovation Award, as well as the George Canellos Award for Excellence in Clinical Investigation and Patient Care. She enjoys a worldwide reputation as a CLL expert and is in much demand as an international speaker.
Agents close to approval in CLL: Zanubrutinib
Barts Cancer Institute, London, UK
Agents close to approval in CLL: Umbralisib
The Ohio State University Comprehensive Cancer Centre, Columbus, USA
Dr. Jennifer Woyach is an Associate Professor in the Division of Hematology at The Ohio State University. As a member of the Leukemia Research Program at the OSUCCC, she focuses her studies on chronic lymphocytic leukemia (CLL) and other hematologic malignancies.
Her research focuses on targeted therapies for CLL and strategies to overcome resistance to targeted therapies. Dr. Woyach led the collaborative effort which identified the mechanism of resistance to the BTK inhibitor ibrutinib (Imbruvica) in CLL and has led preclinical and clinical studies to identify drugs which can overcome ibrutinib- resistance.
Most recently, she led a multi-institutional Phase III clinical trial that showed older patients with CLL have a significantly lower rate of disease progression if treated with ibrutinib rather than with bendamustine (Treanda) plus rituximab (Rituxan)—a regimen previously considered as one of the most effective therapies for this group of patients. It was the first head-to-head comparison between the two treatments. Results were reported simultaneously in the New England Journal of Medicine (NEJM) and in the plenary session at the American Society of Hematology (ASH) 2018 Annual Meeting.
Dr. Woyach has co-authored more than 75 articles in such well-respected publications as NEJM, Lancet Oncology, Blood and Cancer Discovery. She has also shared her research at multiple conferences, including ASH, the American Society of Clinical Oncology (ASCO) Annual Meeting and the International Workshop on Chronic Lymphocytic Leukemia (iwCLL).
Non-covalent BTK inhibitors: ARQ
Maria Sklodowska-Curie National Reseach Institute of Oncology, Krakow, Poland
Wojciech Jurczak is a consultant and professor of hematology at Jagiellonian University, Cracow, Poland where he leads the lymphoma team since 1992.
Most of his research activity in the first 15 years was related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation. At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in monotherapy or as an element of Z-BEAM conditioned ASCT.
During the last decade in Hematology, numerous drugs, with an alternative mechanism of action to classical cytostatics were developed.
Jagiellonian University Lymphoma he leads, participated in over 70 clinical trials, including phase I and phase I followed by expansion cohorts. Wojciech Jurczak is a co-author of publications leading to registration of Ibrutinib, Idelalisib, Belinostat, Lenalidomide, Venetoclax and Rituximab biosimilars. At present his research is focused on developing II generation BTK inhibitors, antiPD1 molecules, DARTs and BITEs.
He is a member of numerous scientific societies (ASH, ASCO, PLRG, EMCLN and ICOS) and consultant for EMA (European Medicines Agency). His research papers were published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc. Cumulative IF > 650, H-index – 20 and citations > 3000.
Non-covalent BTK inhibitors: LOXO
Huntsman Cancer Institute, University of Utah, USA
Deborah Stephens, DO is the Director of the Chronic Lymphocytic Leukemia (CLL)/Lymphoma Program at the Huntsman Cancer Institute at the University of Utah. She completed her internal medicine residency at Cleveland Clinic and fellowship training at The Ohio State University. Dr. Stephens leads a subspecialty clinic with a focus on patients with CLL and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL.
She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials including the international principal investigator for the SWOG S1925 EVOLVE CLL Study (NCT04269902). She is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrates her deep commitment to improving the care of patients with CLL and lymphoma.
High Risk CLL: Therapy
Ulm University, Germany
Dr. Stephan Stilgenbauer is Professor in the Department of Hematology, Oncology, Rheumatology and Infectious Diseases at the University of Ulm, Germany. He received his medical training at Ruprecht-Karls Universität Heidelberg Medical School, Germany with electives in Hamilton, Canada; Jerusalem, Israel; Bath, UK and Cambridge, UK. He went on to complete his final year at the Baylor College of Medicine and MD Anderson Cancer Center in Houston, Texas. His research is focused on the investigation of molecular factors in pathogenesis, and prognosis of CLL and other lymphomas as well as the development of novel treatment approaches for these diseases. Dr. Stilgenbauer has authored or co-authored numerous original articles, reviews and book chapters in journals such as the New England Journal of Medicine, Lancet, Nature, Nature Medicine, Journal of Clinical Oncology, Blood, Leukemia, Oncogene, and Haematologica. Dr. Stilgenbauer has received research support from AbbVie, Amgen, Boehringer-Ingelheim, Celgene, Genentech, Genzyme, Gilead, GSK, Janssen, Mundipharma, Novartis, Pharmacyclics, Hoffmann La-Roche and Sanofi.
High Risk CLL: Biology
City of Hope, California, USA
Tanya Siddiqi, M.D., is an accomplished hematologist-oncologist who specializes in diagnosing and treating blood cancers, particularly Chronic Lymphocytic Leukemia (CLL) and B-cell Non-Hodgkin Lymphoma (B-NHL). She is also a supervising physician at City of Hope's anti-coagulation clinic, which treats patient with blood clotting disorders due to their diseases or treatments.
In addition to her clinical practice, Dr. Siddiqi is also principal investigator on a number of clinical trials evaluating the role of targeted therapies, including gene therapy (CAR T cell therapy), and other novel agents primarily in diseases like CLL and B-NHL.
Dr. Siddiqi earned her medical degree at Aga Khan University Medical College in Karachi, Pakistan. Afterward, she completed an internal medicine residency at University of Connecticut Health Center, followed by fellowships in hematology/oncology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston) and hematopoietic stem cell transplantation at City of Hope.
Dr. Siddiqi is a member of the Immunotherapy Disease Team, Toni Stephenson Lymphoma Center, and the Gehr Family Center for Leukemia Research.
CART in CLL
University of Heidelberg, Germany
Peter Dreger started his scientific career at the University of Kiel, Germany. In 2005 he accepted the position of Professor and Head of the Division of Stem Cell Transplantation at the University of Heidelberg, where he is also running the clinical CLL and CAR T-cell programs.
Peter Dreger is a founding member of the German CLL Study Group and he has been a panel member since then. He served as chairman of the CLL subcommittee of the EBMT Chronic Leukemia WP from 2005 to 2010 and as chairman of the EBMT Lymphoma Working Party from 2010 to 2016. He is a member of the Board of the German Society for Hematology and Oncology and founding member and Speaker of the Cellular Therapy Working Group of the German Lymphoma Alliance (GLA). He is also the current Speaker of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT, formerly DAG-KBT).
Allo SCT in CLL
Leeds Teaching Hospitals NHS Trust, UK
Dr. Andy Rawstron qualified from Edinburgh University with a BSc in Immunology in 1992. He became a Clinical Scientist at the Haematological Malignancy Diagnostic Service in Leeds and was awarded a Doctorate of Philosophy in 2002.
Dr. Rawstron's work into the understanding of CLL, both in terms of defining the nature of Monoclonal B-Lymphocytosis and in developing and standardizing the assessment of minimal residual disease (MRD) in CLL, has been internationally recognized. His work in coordinating a standard approach to MRD analysis in CLL has encouraged close collaboration between many of the laboratories on the cutting edge of CLL research.
Dr. Rawstron has a "routine" service commitment in the development, selection and interpretation of relevant tests for the diagnosis, treatment and monitoring of haematological malignancy.
Within this role he has developed a National award-winning service for monitoring people with MGUS (monoclonal gammopathy of unknown significance) or early stage CLL.
Proposal to improve ESCCA: to facilitate the formation of collaborative groups within ESCCA aimed at developing harmonised clinical cytometry assays.
MRD: Methodology
University of Calgary, Canada
Dr. Owen's previous research has focused largely on the molecular basis of familial MDS and AML and she continues to investigate families with inherited hematological malignancies. Despite her research interest in myeloid neoplasms, her clinical work is focused on lymphoma and chronic lymphocytic leukemia and she has a research focus on clinical trials with significant national leadership in CLL clinical trials.
MRD: Clinical importance
The Ohio State University Comprehensive Cancer Centre, Columbus, USA
Dr. Jennifer Woyach is an Associate Professor in the Division of Hematology at The Ohio State University. As a member of the Leukemia Research Program at the OSUCCC, she focuses her studies on chronic lymphocytic leukemia (CLL) and other hematologic malignancies.
Her research focuses on targeted therapies for CLL and strategies to overcome resistance to targeted therapies. Dr. Woyach led the collaborative effort which identified the mechanism of resistance to the BTK inhibitor ibrutinib (Imbruvica) in CLL and has led preclinical and clinical studies to identify drugs which can overcome ibrutinib- resistance.
Most recently, she led a multi-institutional Phase III clinical trial that showed older patients with CLL have a significantly lower rate of disease progression if treated with ibrutinib rather than with bendamustine (Treanda) plus rituximab (Rituxan)—a regimen previously considered as one of the most effective therapies for this group of patients. It was the first head-to-head comparison between the two treatments. Results were reported simultaneously in the New England Journal of Medicine (NEJM) and in the plenary session at the American Society of Hematology (ASH) 2018 Annual Meeting.
Dr. Woyach has co-authored more than 75 articles in such well-respected publications as NEJM, Lancet Oncology, Blood and Cancer Discovery. She has also shared her research at multiple conferences, including ASH, the American Society of Clinical Oncology (ASCO) Annual Meeting and the International Workshop on Chronic Lymphocytic Leukemia (iwCLL).
Non-covalent BTK inhibitors: ARQ
Maria Sklodowska-Curie National Reseach Institute of Oncology, Krakow, Poland
Wojciech Jurczak is a consultant and professor of hematology at Jagiellonian University, Cracow, Poland where he leads the lymphoma team since 1992.
Most of his research activity in the first 15 years was related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation. At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in monotherapy or as an element of Z-BEAM conditioned ASCT.
During the last decade in Hematology, numerous drugs, with an alternative mechanism of action to classical cytostatics were developed.
Jagiellonian University Lymphoma he leads, participated in over 70 clinical trials, including phase I and phase I followed by expansion cohorts. Wojciech Jurczak is a co-author of publications leading to registration of Ibrutinib, Idelalisib, Belinostat, Lenalidomide, Venetoclax and Rituximab biosimilars. At present his research is focused on developing II generation BTK inhibitors, antiPD1 molecules, DARTs and BITEs.
He is a member of numerous scientific societies (ASH, ASCO, PLRG, EMCLN and ICOS) and consultant for EMA (European Medicines Agency). His research papers were published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc. Cumulative IF > 650, H-index – 20 and citations > 3000.
Non-covalent BTK inhibitors: LOXO
Huntsman Cancer Institute, University of Utah, USA
Deborah Stephens, DO is the Director of the Chronic Lymphocytic Leukemia (CLL)/Lymphoma Program at the Huntsman Cancer Institute at the University of Utah. She completed her internal medicine residency at Cleveland Clinic and fellowship training at The Ohio State University. Dr. Stephens leads a subspecialty clinic with a focus on patients with CLL and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL.
She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials including the international principal investigator for the SWOG S1925 EVOLVE CLL Study (NCT04269902). She is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrates her deep commitment to improving the care of patients with CLL and lymphoma.
High Risk CLL: Therapy
Ulm University, Germany
Dr. Stephan Stilgenbauer is Professor in the Department of Hematology, Oncology, Rheumatology and Infectious Diseases at the University of Ulm, Germany. He received his medical training at Ruprecht-Karls Universität Heidelberg Medical School, Germany with electives in Hamilton, Canada; Jerusalem, Israel; Bath, UK and Cambridge, UK. He went on to complete his final year at the Baylor College of Medicine and MD Anderson Cancer Center in Houston, Texas. His research is focused on the investigation of molecular factors in pathogenesis, and prognosis of CLL and other lymphomas as well as the development of novel treatment approaches for these diseases. Dr. Stilgenbauer has authored or co-authored numerous original articles, reviews and book chapters in journals such as the New England Journal of Medicine, Lancet, Nature, Nature Medicine, Journal of Clinical Oncology, Blood, Leukemia, Oncogene, and Haematologica. Dr. Stilgenbauer has received research support from AbbVie, Amgen, Boehringer-Ingelheim, Celgene, Genentech, Genzyme, Gilead, GSK, Janssen, Mundipharma, Novartis, Pharmacyclics, Hoffmann La-Roche and Sanofi.
High Risk CLL: Biology
MD Anderson Cancer Center, Houston, Texas, USA
Dr. William G. Wierda is a professor and center medical director for the Department of Leukemia at MD Anderson Cancer Center. Dr. Wierda earned his PhD in 1992 and MD in 1993 from University of Health Sciences at Chicago Medical School and his post-graduate education in internal medicine was at Duke University. This was followed by a fellowship in Hematology/Oncology at University of California at San Diego, where he was trained under the mentorship of Dr. Thomas Kipps. Dr. Wierda’s particular research interests in CLL are prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.
Dr. Wierda is head of the CLL section in the Department of Leukemia, where he is directing the clinical and translational efforts in CLL and low-grade lymphoproliferative diseases. Dr. Wierda is also the director of the clinical core and clinical research of the CLL Research Consortium (CRC), a multicenter PO1 project headed by Dr. Thomas Kipps at UCSD. In his role, Dr. Wierda is directing and coordinating CLL-related clinical research activities at the participating sites, including Mayo Clinic, The Ohio State University, UCSD, Dana Farber Cancer Institute, Long Island Jewish Hospital, as well as MD Anderson Cancer Center. For the past several years he has served on the NCCN Lymphoma Panel providing leadership and recommendations for CLL treatment in the NCCN guidelines. He has published many articles in high-impact peer-reviewed journals on various clinical and translational aspects of CLL and drug development and given numerous lectures at national and international scientific meetings.
There is still a role for Chemoimmunotherapy in CLL
University Hospital Cologne, Germany
Barbara Eichhorst is Associate Professor and Attending Physician at the University Hospital Cologne, Cologne, Germany.
She studied medicine at the Ludwig-Maiximilians-Universität (LMU) in Munich, Germany from 1990 to 1997. In 1998, she moved to the Medical Clinic III of Professor Wolfgang Hiddemann at the Klinikum Großhadern of the LMU.
In 2005, she joined the Internal Medicine clinic of Professor Michael Hallek at the University Hospital Cologne, Cologne, Germany and completed her training as a medical oncologist and hematologist with a focus on chronic lymphocytic leukemia (CLL) in 2006.
Dr Eichorst has worked for the German CLL Study Group (GCLLSG) initially as a coordinating doctor and then as a Principal Investigator since 1997. As of 2005, she is secretary of the German CLL Study Group (DCLLSG).
There is no role for Chemoimmunotherapy in CLL
University of Amsterdam, The Netherlands
Prof. Dr. Arnon Kater is professor of Translational Hematology at the University of Amsterdam’s faculty of Medicine (AMC-UvA). His fundamental, translational and clinical research as a Clinical Hematologist is focused on lymphatic cancer (lymphoma), in particular chronic lymphatic leukemia (CLL). He is one of the founders of the Lymphoma and Myeloma Center Amsterdam (LYMMCARE), a specialist knowledge center where the AMC-UvA’s Clinical Hematology, Experimental Immunology, and Pathology departments have joined forces since 2012. Within the Amsterdam University Medical Center, he is deputy head of the Department of Hematology, Dean of the Hematology Specialty Program, and chairman of the Good Clinical Research Committee. In addition, he chairs the Dutch CLL working group at the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON) and is a member of the editorial board of the journals Blood and Haematologica. In collaborations with various pharma companies, Prof. Kater is involved in developments leading to new treatment modalities.
Prof. Kater was trained as an internist (hematologist) at the AMC-UvA. In 2006, he obtained his PhD in research into cell death regulation in CLL cells. Prof. Kater has been a staff member of the Internal Medicine Department at the AMC-UvA since 2007, and principal researcher in Clinical Hematology since 2012. From 2008 to 2009 he also worked as a postdoc at the Moores Cancer Center and the Laboratory of Gene Regulation and Signal Transduction at the University of California (San Diego, US). He co-authored over 100 manuscripts that together have been cited more than 4,000 times.
Sequencing BTKi and Venetoclax
Memorial Sloan Kettering Cancer Center, New York, USA
Anthony R Mato, MD, MSCE, is an Associate Member at Memorial Sloan Kettering Cancer Center and Director of the Chronic Lymphocytic Leukemia (CLL) Program at MSKCC. He received his medical degree from the State University of New York (SUNY) at Buffalo, and completed his internal medicine residency and hematology/oncology fellowship at the Hospital of the University of Pennsylvania. While at Penn, Dr Mato also earned a master's degree in clinical epidemiology. His research on the development of clinical and translational trials for patients with CLL and lymphoproliferative disorders focuses on novel immunotherapies, signal transduction inhibitors, immune checkpoint inhibitors, and immunotherapy agents. His outcomes-related research explores a wide variety of health indicators among CLL patients in real world settings. He has been the principal investigator on numerous clinical trials for patients with CLL and is currently overseeing several ongoing clinical trials, some of which are actively enrolling patients. A well-published scholar, he regularly contributes articles to peer-reviewed journals, including Blood, the British Journal of Hematology, Annals of Oncology, Heamatologica, Lancet Oncology, and the American Journal of Hematology. Dr Mato is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physician Executives. He is also on the medical advisory board of the CLL Society, a patient-centric, physician-curated nonprofit organization focused on patient education and support.
Real World Data with Venetoclax
Institute of Oncology Research, Bellinzona, Switzerland
Prof. Davide Rossi obtained the specialization in Internal Medicine and the PhD in Clinical and Experimental Medicine at the University of Eastern Piedmont, where he served as Professor of Hematology until 2015. In 2015 Prof. Rossi moved to Switzerland, where he is head of the Experimental Hematology research program at the IOR, Deputy Head of the Division of Hematology and co-chair of the Clinical Lymphoid Tumors Investigation Program at the Oncology Institute of Southern Switzerland (IOSI). Prof. Rossi’s research focuses on lymphomas and chronic lymphocytic leukemia, with more than 330 publications in international peer-reviewed journals. He is also the principal investigator of national and international clinical trials in the field of chronic lymphocytic leukemia. Prof. Rossi contributed to the development of chronic lymphocytic leukemia guidelines and co-authored the 2016 WHO Classification of Hematologic Malignancies. He serves as Editorial Board Member of Blood (the official Journal of the American Society of Hematology), Blood Cancer Discovery, and HaemaSphere (the official Journal of the European Hematology Association). Prof. Rossi is member of the Organizing Committees of the International Conference on Malignant Lymphoma (ICML) and of the Congress of the European Hematology Association (EHA). Prof. Rossi’s research is funded by grants from the European Research Council, Swiss National Fund, Oncosuisse, Leukemia and Lymphoma Society, Fond’Action and Dr. Ettore Balli Foundation.
Richters syndrome: Richters Biology
Columbia University Herbert Irving Comprehensive Cancer Center, USA
Nicole Lamanna, MD, is an Associate Clinical Professor of Medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division. Dr. Lamanna is a hematologist/oncologist whose research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia.
She is an experienced clinical investigator and her research focus has been the development of combination therapies that include chemoimmunotherapy, immunomodulatory drugs, novel kinase inhibitors and monoclonal antibodies. She also is working to find active, safer therapies for older patients with these diseases.
She earned her medical degree from Albert Einstein College of Medicine and completed her fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.
Richters syndrome: Richters Therapy
University of California Irvine Medical Center, USA
Susan M. O’Brien, M.D., is a professor in the department of leukemia and clinical consultant and special assistant to the physician-in-chief at MD Anderson Cancer Center. Dr. O’Brien received her medical degree from the University of Medicine and Dentistry of New Jersey in Newark. She went on to complete a residency in internal medicine at the University of Medicine and Dentistry of New Jersey. She served there as an instructor in medicine before moving to California, where she served as an instructor in the San Fernando Valley Program in the University of California, Los Angeles School of Medicine and an internist in the University of Southern California Student Health Service. During her time at MD Anderson, Dr. O’Brien has been the principal investigator or a co-principal investigator for 5 funded research projects and the primary investigator for more than 20 funded protocols. In addition, she has served on the Translational Research Study Section for the Leukemia and Lymphoma Society since 2001.
Next Questions in CLL
University of Oxford, UK
Professor Anna Schuh is the Director of Molecular Diagnostics at the University of Oxford and an Honorary Consultant Haematologist. She is the clinical lead for chronic lymphocytic leukaemia (CLL) and other lymphoproliferative disorders for the NHS Thames Valley Cancer Network.
Over the past ten years she has led over 30 early and late phase clinical trials in CLL as a principle or national chief investigator. A number of these led to NICE approvals and have changed clinical practice for patients with CLL in the UK and worldwide. She chaired the UK CLL Forum from 2016 to 2019 that aims to promote research and education in CLL nationally and she led the treatment guidelines writing group for CLL on behalf of the British Society of Haematology. In August 2018, she was appointed as the chair for the National Cancer Research Institute CLL working group.
NGS in CLL, what does it add
City of Hope, California, USA
Tanya Siddiqi, M.D., is an accomplished hematologist-oncologist who specializes in diagnosing and treating blood cancers, particularly Chronic Lymphocytic Leukemia (CLL) and B-cell Non-Hodgkin Lymphoma (B-NHL). She is also a supervising physician at City of Hope's anti-coagulation clinic, which treats patient with blood clotting disorders due to their diseases or treatments.
In addition to her clinical practice, Dr. Siddiqi is also principal investigator on a number of clinical trials evaluating the role of targeted therapies, including gene therapy (CAR T cell therapy), and other novel agents primarily in diseases like CLL and B-NHL.
Dr. Siddiqi earned her medical degree at Aga Khan University Medical College in Karachi, Pakistan. Afterward, she completed an internal medicine residency at University of Connecticut Health Center, followed by fellowships in hematology/oncology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston) and hematopoietic stem cell transplantation at City of Hope.
Dr. Siddiqi is a member of the Immunotherapy Disease Team, Toni Stephenson Lymphoma Center, and the Gehr Family Center for Leukemia Research.
CART in CLL
University of Heidelberg, Germany
Peter Dreger started his scientific career at the University of Kiel, Germany. In 2005 he accepted the position of Professor and Head of the Division of Stem Cell Transplantation at the University of Heidelberg, where he is also running the clinical CLL and CAR T-cell programs.
Peter Dreger is a founding member of the German CLL Study Group and he has been a panel member since then. He served as chairman of the CLL subcommittee of the EBMT Chronic Leukemia WP from 2005 to 2010 and as chairman of the EBMT Lymphoma Working Party from 2010 to 2016. He is a member of the Board of the German Society for Hematology and Oncology and founding member and Speaker of the Cellular Therapy Working Group of the German Lymphoma Alliance (GLA). He is also the current Speaker of the German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy (DAG-HSZT, formerly DAG-KBT).
Allo SCT in CLL
Leeds Teaching Hospitals NHS Trust, UK
Dr. Andy Rawstron qualified from Edinburgh University with a BSc in Immunology in 1992. He became a Clinical Scientist at the Haematological Malignancy Diagnostic Service in Leeds and was awarded a Doctorate of Philosophy in 2002.
Dr. Rawstron's work into the understanding of CLL, both in terms of defining the nature of Monoclonal B-Lymphocytosis and in developing and standardizing the assessment of minimal residual disease (MRD) in CLL, has been internationally recognized. His work in coordinating a standard approach to MRD analysis in CLL has encouraged close collaboration between many of the laboratories on the cutting edge of CLL research.
Dr. Rawstron has a "routine" service commitment in the development, selection and interpretation of relevant tests for the diagnosis, treatment and monitoring of haematological malignancy.
Within this role he has developed a National award-winning service for monitoring people with MGUS (monoclonal gammopathy of unknown significance) or early stage CLL.
Proposal to improve ESCCA: to facilitate the formation of collaborative groups within ESCCA aimed at developing harmonised clinical cytometry assays.
MRD: Methodology
University of Calgary, Canada
Dr. Owen's previous research has focused largely on the molecular basis of familial MDS and AML and she continues to investigate families with inherited hematological malignancies. Despite her research interest in myeloid neoplasms, her clinical work is focused on lymphoma and chronic lymphocytic leukemia and she has a research focus on clinical trials with significant national leadership in CLL clinical trials.
MRD: Clinical importance
MD Anderson Cancer Center, Houston, Texas, USA
Dr. William G. Wierda is a professor and center medical director for the Department of Leukemia at MD Anderson Cancer Center. Dr. Wierda earned his PhD in 1992 and MD in 1993 from University of Health Sciences at Chicago Medical School and his post-graduate education in internal medicine was at Duke University. This was followed by a fellowship in Hematology/Oncology at University of California at San Diego, where he was trained under the mentorship of Dr. Thomas Kipps. Dr. Wierda’s particular research interests in CLL are prognostic factors and developing prognostic models in CLL, immune and gene therapies for patients with CLL, developing chemoimmunotherapy regimens and treatment strategies for relapsed and refractory patients with CLL.
Dr. Wierda is head of the CLL section in the Department of Leukemia, where he is directing the clinical and translational efforts in CLL and low-grade lymphoproliferative diseases. Dr. Wierda is also the director of the clinical core and clinical research of the CLL Research Consortium (CRC), a multicenter PO1 project headed by Dr. Thomas Kipps at UCSD. In his role, Dr. Wierda is directing and coordinating CLL-related clinical research activities at the participating sites, including Mayo Clinic, The Ohio State University, UCSD, Dana Farber Cancer Institute, Long Island Jewish Hospital, as well as MD Anderson Cancer Center. For the past several years he has served on the NCCN Lymphoma Panel providing leadership and recommendations for CLL treatment in the NCCN guidelines. He has published many articles in high-impact peer-reviewed journals on various clinical and translational aspects of CLL and drug development and given numerous lectures at national and international scientific meetings.
There is still a role for Chemoimmunotherapy in CLL
University Hospital Cologne, Germany
Barbara Eichhorst is Associate Professor and Attending Physician at the University Hospital Cologne, Cologne, Germany.
She studied medicine at the Ludwig-Maiximilians-Universität (LMU) in Munich, Germany from 1990 to 1997. In 1998, she moved to the Medical Clinic III of Professor Wolfgang Hiddemann at the Klinikum Großhadern of the LMU.
In 2005, she joined the Internal Medicine clinic of Professor Michael Hallek at the University Hospital Cologne, Cologne, Germany and completed her training as a medical oncologist and hematologist with a focus on chronic lymphocytic leukemia (CLL) in 2006.
Dr Eichorst has worked for the German CLL Study Group (GCLLSG) initially as a coordinating doctor and then as a Principal Investigator since 1997. As of 2005, she is secretary of the German CLL Study Group (DCLLSG).
There is no role for Chemoimmunotherapy in CLL
University of Amsterdam, The Netherlands
Prof. Dr. Arnon Kater is professor of Translational Hematology at the University of Amsterdam’s faculty of Medicine (AMC-UvA). His fundamental, translational and clinical research as a Clinical Hematologist is focused on lymphatic cancer (lymphoma), in particular chronic lymphatic leukemia (CLL). He is one of the founders of the Lymphoma and Myeloma Center Amsterdam (LYMMCARE), a specialist knowledge center where the AMC-UvA’s Clinical Hematology, Experimental Immunology, and Pathology departments have joined forces since 2012. Within the Amsterdam University Medical Center, he is deputy head of the Department of Hematology, Dean of the Hematology Specialty Program, and chairman of the Good Clinical Research Committee. In addition, he chairs the Dutch CLL working group at the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON) and is a member of the editorial board of the journals Blood and Haematologica. In collaborations with various pharma companies, Prof. Kater is involved in developments leading to new treatment modalities.
Prof. Kater was trained as an internist (hematologist) at the AMC-UvA. In 2006, he obtained his PhD in research into cell death regulation in CLL cells. Prof. Kater has been a staff member of the Internal Medicine Department at the AMC-UvA since 2007, and principal researcher in Clinical Hematology since 2012. From 2008 to 2009 he also worked as a postdoc at the Moores Cancer Center and the Laboratory of Gene Regulation and Signal Transduction at the University of California (San Diego, US). He co-authored over 100 manuscripts that together have been cited more than 4,000 times.
Sequencing BTKi and Venetoclax
Memorial Sloan Kettering Cancer Center, New York, USA
Anthony R Mato, MD, MSCE, is an Associate Member at Memorial Sloan Kettering Cancer Center and Director of the Chronic Lymphocytic Leukemia (CLL) Program at MSKCC. He received his medical degree from the State University of New York (SUNY) at Buffalo, and completed his internal medicine residency and hematology/oncology fellowship at the Hospital of the University of Pennsylvania. While at Penn, Dr Mato also earned a master's degree in clinical epidemiology. His research on the development of clinical and translational trials for patients with CLL and lymphoproliferative disorders focuses on novel immunotherapies, signal transduction inhibitors, immune checkpoint inhibitors, and immunotherapy agents. His outcomes-related research explores a wide variety of health indicators among CLL patients in real world settings. He has been the principal investigator on numerous clinical trials for patients with CLL and is currently overseeing several ongoing clinical trials, some of which are actively enrolling patients. A well-published scholar, he regularly contributes articles to peer-reviewed journals, including Blood, the British Journal of Hematology, Annals of Oncology, Heamatologica, Lancet Oncology, and the American Journal of Hematology. Dr Mato is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physician Executives. He is also on the medical advisory board of the CLL Society, a patient-centric, physician-curated nonprofit organization focused on patient education and support.
Real World Data with Venetoclax
Institute of Oncology Research, Bellinzona, Switzerland
Prof. Davide Rossi obtained the specialization in Internal Medicine and the PhD in Clinical and Experimental Medicine at the University of Eastern Piedmont, where he served as Professor of Hematology until 2015. In 2015 Prof. Rossi moved to Switzerland, where he is head of the Experimental Hematology research program at the IOR, Deputy Head of the Division of Hematology and co-chair of the Clinical Lymphoid Tumors Investigation Program at the Oncology Institute of Southern Switzerland (IOSI). Prof. Rossi’s research focuses on lymphomas and chronic lymphocytic leukemia, with more than 330 publications in international peer-reviewed journals. He is also the principal investigator of national and international clinical trials in the field of chronic lymphocytic leukemia. Prof. Rossi contributed to the development of chronic lymphocytic leukemia guidelines and co-authored the 2016 WHO Classification of Hematologic Malignancies. He serves as Editorial Board Member of Blood (the official Journal of the American Society of Hematology), Blood Cancer Discovery, and HaemaSphere (the official Journal of the European Hematology Association). Prof. Rossi is member of the Organizing Committees of the International Conference on Malignant Lymphoma (ICML) and of the Congress of the European Hematology Association (EHA). Prof. Rossi’s research is funded by grants from the European Research Council, Swiss National Fund, Oncosuisse, Leukemia and Lymphoma Society, Fond’Action and Dr. Ettore Balli Foundation.
Richters syndrome: Richters Biology
Columbia University Herbert Irving Comprehensive Cancer Center, USA
Nicole Lamanna, MD, is an Associate Clinical Professor of Medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division. Dr. Lamanna is a hematologist/oncologist whose research interests include lymphoid leukemias, specifically chronic lymphocytic leukemia.
She is an experienced clinical investigator and her research focus has been the development of combination therapies that include chemoimmunotherapy, immunomodulatory drugs, novel kinase inhibitors and monoclonal antibodies. She also is working to find active, safer therapies for older patients with these diseases.
She earned her medical degree from Albert Einstein College of Medicine and completed her fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center.
Richters syndrome: Richters Therapy
University of California Irvine Medical Center, USA
Susan M. O’Brien, M.D., is a professor in the department of leukemia and clinical consultant and special assistant to the physician-in-chief at MD Anderson Cancer Center. Dr. O’Brien received her medical degree from the University of Medicine and Dentistry of New Jersey in Newark. She went on to complete a residency in internal medicine at the University of Medicine and Dentistry of New Jersey. She served there as an instructor in medicine before moving to California, where she served as an instructor in the San Fernando Valley Program in the University of California, Los Angeles School of Medicine and an internist in the University of Southern California Student Health Service. During her time at MD Anderson, Dr. O’Brien has been the principal investigator or a co-principal investigator for 5 funded research projects and the primary investigator for more than 20 funded protocols. In addition, she has served on the Translational Research Study Section for the Leukemia and Lymphoma Society since 2001.
Next Questions in CLL
University of Oxford, UK
Professor Anna Schuh is the Director of Molecular Diagnostics at the University of Oxford and an Honorary Consultant Haematologist. She is the clinical lead for chronic lymphocytic leukaemia (CLL) and other lymphoproliferative disorders for the NHS Thames Valley Cancer Network.
Over the past ten years she has led over 30 early and late phase clinical trials in CLL as a principle or national chief investigator. A number of these led to NICE approvals and have changed clinical practice for patients with CLL in the UK and worldwide. She chaired the UK CLL Forum from 2016 to 2019 that aims to promote research and education in CLL nationally and she led the treatment guidelines writing group for CLL on behalf of the British Society of Haematology. In August 2018, she was appointed as the chair for the National Cancer Research Institute CLL working group.
NGS in CLL, what does it add
Each expert presentation is followed by a question and answer session with one of the co-chairs and includes downloadable slides to enhance understanding.
Release date: January 2022
Expiration date: December 2023
Estimated time to complete activity: up to a maximum of 12 Hours
If required, please contact MER on +1 800-421-3756
Link to MER Privacy Policy http://cmepartner.org/privacy-policy/
This activity is jointly provided by Medical Education Resources and MD Education Ltd.
UK OFFICE
4/4a Bloomsbury Square,
London,
United Kingdom
WC1A 2RP
US OFFICE
MD Education USA, LLC
4600 140th Avenue North
Suite 180
Clearwater, FL 33762
UK OFFICE
4/4a Bloomsbury Square,
London,
United Kingdom
WC1A 2RP
US OFFICE
MD Education USA, LLC
4600 140th Avenue North
Suite 180
Clearwater, FL 33762
© Copyright MD Education 2022 | Privacy Policy | Terms & Conditions | Organised by MD Education
Developed by: Unet
Susan M. O’Brien, M.D., is a professor in the department of leukemia and clinical consultant and special assistant to the physician-in-chief at MD Anderson Cancer Center. Dr. O’Brien received her medical degree from the University of Medicine and Dentistry of New Jersey in Newark. She went on to complete a residency in internal medicine at the University of Medicine and Dentistry of New Jersey. She served there as an instructor in medicine before moving to California, where she served as an instructor in the San Fernando Valley Program in the University of California, Los Angeles School of Medicine and an internist in the University of Southern California Student Health Service. During her time at MD Anderson, Dr. O’Brien has been the principal investigator or a co-principal investigator for 5 funded research projects and the primary investigator for more than 20 funded protocols. In addition, she has served on the Translational Research Study Section for the Leukemia and Lymphoma Society since 2001.
Dr. John Gribben is a professor and medical oncologist at Barts Cancer Institute in London, United Kingdom. He specializes in hematology/oncology; lymphoma; chronic lymphocytic leukemia; and bone marrow transplantation. Dr. Gribben received his medical training from the University of Glasgow, University College London and Harvard Medical School. He is a member of the CLL Research Consortium and has more than 200 peer-reviewed articles in medical journals.
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Othman Al-Sawaf MD
University of Cologne, Germany
John Seymour
Peter MacCallum Cancer Centre, Melbourne, Australia
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Jacqueline Barrientos
Feinstein Institutes for Medical Research, New York, USA
Paolo Ghia
Università Vita-Salute San Raffaele, Milan, Italy
Ian Flinn Presentation
Ian Flinn Overview
Ian Flinn PDF presentation download
Carol Moreno Presentation
Carol Moreno Overview
Carol Moreno PDF presentation download
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Carol Moreno
Hospital de Sant Pau i Santa Creu, Barcelona, Spain
Ian Flinn
Tennessee Oncology, Nashville, USA
Jennifer Brown – Presentation
Jennifer Brown – Overview
John Gribben- Presentation
John Gribben – Overview
Faculty Q&A
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Jennifer Brown
Dana-Farber Cancer Institute, Boston, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Jennifer Woyach Presentation
Jennifer Woyach Overview
Jennifer Woyach Slide
Wojciech Jurczak Presentation
Wojciech Jurczak Overview
Wojciech Jurczak Slide
Faculty Q&A
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Jennifer Woyach
The Ohio State University Comprehensive Cancer Centre, Columbus, USA
Wojciech Jurczak
Maria Sklodowska-Curie National Reseach Institute of Oncology, Krakow, Poland
Deborah Stephens – Presentation
Deborah Stephens – Overview
Deborah Stephens – Slide
Stephan Stilgenbauer – Presentation
Stephan Stilgenbauer – Overview
Stephan Stilgenbauer – Slide
Faculty Q&A
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Deborah Stephens
Huntsman Cancer Institute, University of Utah, USA
Stephan Stilgenbauer
Ulm University, Germany
Peter Dreger – Presentation
Peter Dreger – Q&A
Peter Dreger – Slide
Tanya Siddiqi – Slide
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Tanya Siddiqi
City of Hope, California, USA
Peter Dreger
University of Heidelberg, Germany
Carolyn Owen – Presentation
Carolyn Owen – Highlight
Carolyn Owen – Slides
Andy Rawstron – Presentation
Andy Rawstron – Highlight
Andy Rawstron – Slides
Q&A
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Andy Rawstron
Leeds Teaching Hospitals NHS Trust, UK
Carolyn Owen
University of Calgary, Canada
Bill Wierda – Presentation
Bill Wierda – Highlight
Bill Wierda – Q&A
Barbara Eichhorst – Presentation
Barbara Eichhorst – Highlight
Q&A
Barbara Eichhorst – Slides
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Bill Wierda
MD Anderson Cancer Center, Houston, Texas, USA
Barbara Eichhorst
University Hospital Cologane, Germany
PDF PRESENTATION DOWNLOAD
Arnon Kater – Presentation
Arnon Kater- Summary
Arnon Kater- Slides
Anthony Mato – Presentation
Anthony Mato – Summary
Anthony Mato – Slides
Q&A
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Arnon Kater
University of Amsterdam, The Natherlands
Anthony Mato
Memorial Sloan Kettering Cancer Center, New York, USA
Davide Rossi – Presentation
Davide Rossi – Summary
Q&A
Nicole Lamanna – Presentation
Nicole Lamanna – Slides
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Davide Rossi
Institute of Oncology Research, Bellinozona, Switzerland
Nicole Lamanna
Columbia University Herbert Irving Comprehensive Cancer Center, USA
Anna Schuh – Presentation
Anna Schuh – Summary
Susan O’Brien- Presentation
Susan O’Brien – Summary
Faculty Q&A
Susan O’Brien, M.D
University of California Irvine Medical Center, USA
Prof. John Gribben
Barts Cancer Institute, London, UK
Susan O’Brien, M.D.
University of California Irvine Medical Center, USA
Anna Schuh
University of Oxford, UK
PDF PRESENTATION DOWNLOAD
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In euismod, nulla at dapibus pulvinar, felis quam malesuada mauris, id finibus nulla tortor a metus. Nam in placerat massa. Suspendisse sollicitudin congue malesuada. Praesent accumsan mollis nibh id maximus. Maecenas feugiat purus vel tempor vehicula
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In euismod, nulla at dapibus pulvinar, felis quam malesuada mauris, id finibus nulla tortor a metus. Nam in placerat massa. Suspendisse sollicitudin congue malesuada. Praesent accumsan mollis nibh id maximus. Maecenas feugiat purus vel tempor vehicula
